Boehringer Ingelheim reports positive data from trial of spesolimab for GPP
The new humanised antibody spesolimab is currently indicated to treat GPP flares in adults.
Company News
Aptose Biosciences begins subject dosing in AML therapy trial
FDA clears Escient’s IND for mast cell mediated disorders therapy trial
AmMax Bio doses first subjects in Phase IIb trial of TGCT therapy
Janssen’s trial of CARVYKTI for multiple myeloma meets primary endpoint
Central IRB approves Skye Bioscience’s SBI-100 OE trial
Marengo Therapeutics begins subject dosing in cancer therapy trial
HuidaGene receives FDA clearance for retinal dystrophies therapy trial
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
